Top

BMC Nephrology

Published in:

Open Access 01-12-2023 | Research

Adenine model of chronic renal failure in rats to determine whether MCC950, an NLRP3 inflammasome inhibitor, is a renopreventive

Authors: Mahmoud S. Sabra, Fahmy K. Hemida, Essmat A. H. Allam

Published in: BMC Nephrology | Issue 1/2023

Abstract

Background

Chronic renal failure (CRF) is defined by a significant decline in renal function that results in decreased salt filtration and inhibition of tubular reabsorption, which ultimately causes volume enlargement. This study evaluated the potential renopreventive effects of the NLRP3 inflammasome inhibitor MCC950 in adenine-induced CRF in rats due to conflicting evidence on the effects of MCC950 on the kidney.

Methods

Since the majority of the kidney tubular abnormalities identified in people with chronic renal disease are comparable to those caused by adding 0.75 percent of adenine powder to a rat's diet each day for four weeks, this method has received broad approval as a model for evaluating kidney damage. Throughout the test, blood pressure was checked weekly and at the beginning. Additionally, oxidative stress factors, urine sample examination, histological modifications, and immunohistochemical adjustments of caspase-3 and interleukin-1 beta (IL-1) levels in renal tissues were carried out.

Results

Results revealed that MCC950, an inhibitor of the NLRP3 inflammasome, had a renopreventive effect, which was demonstrated by a reduction in blood pressure readings and an improvement in urine, serum, and renal tissue indicators that indicate organ damage. This was also demonstrated by the decrease in neutrophil gelatinase-associated lipocalin tubular expression (NGAL).

The NLRP3 inflammasome inhibitor MCC950 was found to significantly alleviate the worsening renal cellular alterations evidenced by increased expression of caspase-3 and IL-1, according to immunohistochemical tests.

Conclusion

The NLRP3 inflammasome inhibitor MCC950 demonstrated renopreventive effects in the CRF rat model, suggesting that it might be used as a treatment strategy to stop the progression of CRF.

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294–304.PubMedPubMedCentralCrossRef

Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–78.PubMedCrossRef

Tu H, Ma D, Luo Y, Tang S, Li Y, Chen G, et al. Quercetin alleviates chronic renal failure by targeting the PI3k/Akt pathway. Bioengineered. 2021;12(1):6538–58.PubMedPubMedCentralCrossRef

Aseneh JB, Kemah BLA, Mabouna S, Njang ME, Ekane DSM, Agbor VN. Chronic kidney disease in Cameroon: a scoping review. BMC nephrology. 2020;21(1):1–11.CrossRef

Gyurászová M, Gurecká R, Bábíčková J, Tóthová Ľ. Oxidative stress in the pathophysiology of kidney disease: Implications for noninvasive monitoring and identification of biomarkers. Oxidative medicine and cellular longevity. 2020;2020:5478708. https://doi.org/10.1155/2020/5478708.

Podkowińska A, Formanowicz D. Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease. Antioxidants. 2020;9(8):752.PubMedPubMedCentralCrossRef

Kashioulis P, Lundgren J, Shubbar E, Nguy L, Saeed A, Guron CW, et al. Adenine-induced chronic renal failure in rats: a model of chronic renocardiac syndrome with left ventricular diastolic dysfunction but preserved ejection fraction. Kidney Blood Press Res. 2018;43(4):1053–64.PubMedCrossRef

Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019;34:975–91.PubMedCrossRef

Kanneganti T-D, Lamkanfi M, Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity. 2007;27(4):549–59.PubMedCrossRef

10.

Li L, Tang W, Yi F. Role of inflammasome in chronic kidney disease. Renal Fibrosis: Mechanisms and Therapies. 2019;1165:407–21.

11.

Mulay SR. Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. Kidney Int. 2019;96(1):58–66.PubMedCrossRef

12.

Wu M, Han W, Song S, Du Y, Liu C, Chen N, et al. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice. Mol Cell Endocrinol. 2018;478:115–25.PubMedCrossRef

13.

Zhang H, Wang Z. Effect and regulation of the NLRP3 inflammasome during renal fibrosis. Frontiers in cell and developmental biology. 2020;7:379.PubMedPubMedCentralCrossRef

14.

Ke B, Shen W, Fang X, Wu Q. The NLPR3 inflammasome and obesity-related kidney disease. J Cell Mol Med. 2018;22(1):16–24.PubMedCrossRef

15.

Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21(10):1732.PubMedPubMedCentralCrossRef

16.

Kim MH, Kwak SH, Kim S-H, Hong JS, Chung HR, Choi SH, et al. Gemigliptin attenuates renal fibrosis through down-regulation of the NLRP3 inflammasome. Diabetes Metab J. 2019;43(6):830–9.CrossRef

17.

Wen Y, Pan MM, Lv LL, Tang TT, Zhou LT, Wang B, et al. Artemisinin attenuates tubulointerstitial inflammation and fibrosis via the NF-κB/NLRP3 pathway in rats with 5/6 subtotal nephrectomy. J Cell Biochem. 2019;120(3):4291–300.PubMedCrossRef

18.

Kennedy CR, Goya Grocin A, Kovačič T, Singh R, Ward JA, Shenoy AR, et al. A probe for NLRP3 inflammasome inhibitor MCC950 identifies carbonic anhydrase 2 as a novel target. ACS Chem Biol. 2021;16(6):982–90.PubMedPubMedCentralCrossRef

19.

Matsuoka T, Yoshimatsu G, Sakata N, Kawakami R, Tanaka T, Yamada T, et al. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death. Sci Rep. 2020;10(1):17920.PubMedPubMedCentralCrossRef

20.

Khan N, Kuo A, Brockman DA, Cooper MA, Smith MT. Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. Inflammopharmacology. 2018;26:77–86.PubMedCrossRef

21.

Luo Y, Lu J, Ruan W, Guo X, Chen S. MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats. Brain Res Bull. 2019;146:320–6.PubMedCrossRef

22.

Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–55.PubMedPubMedCentralCrossRef

23.

Dempsey C, Araiz AR, Bryson K, Finucane O, Larkin C, Mills E, et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun. 2017;61:306–16.PubMedCrossRef

24.

Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Scie Translation Medic. 2018;10(465):4066.CrossRef

25.

Zhang C, Zhu X, Li L, Ma T, Shi M, Yang Y, et al. A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation. Diabetes, metabolic syndrome and obesity: targets and therapy. 2019;12:1297–309.

26.

Lin Q, Li S, Jiang N, Jin H, Shao X, Zhu X, et al. Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy. Autophagy. 2021;17(10):2975–90.PubMedCrossRef

27.

Østergaard JA, Jha JC, Sharma A, Dai A, Choi JS, de Haan JB, et al. Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease. Clin Sci. 2022;136(2):167–80.CrossRef

28.

Thakur R, Sharma A, Lingaraju MC, Begum J, Kumar D, Mathesh K, et al. Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats. Biomed Pharmacother. 2018;101:972–80.PubMedCrossRef

29.

Zhao J, Guo X, Wang B, Yang Z, Huang T, Guo D, et al. MCC950 inhibits NLRP3 inflammasome and alleviates axonal injures in early stages of diffuse axonal injury in rats. Neurochem Res. 2020;45:2020–31.PubMedCrossRef

30.

Dong X, Tang Y. Ntrk1 promotes mesangial cell proliferation and inflammation in rat glomerulonephritis model by activating the STAT3 and p38/ERK MAPK signaling pathways. BMC Nephrol. 2022;23(1):413.PubMedPubMedCentralCrossRef

31.

Zhao C, Gao J, Li S, Liu Q, Hou X, Xing X, et al. Cyclin G2 regulates canonical Wnt signalling via interaction with Dapper1 to attenuate tubulointerstitial fibrosis in diabetic nephropathy. J Cell Mol Med. 2020;24(5):2749–60.PubMedPubMedCentralCrossRef

32.

Schlatzer DM, Dazard JE, Dharsee M, Ewing RM, Ilchenko S, Stewart I, et al. Urinary protein profiles in a rat model for diabetic complications. Molecular & cellular proteomics : MCP. 2009;8(9):2145–58.PubMedCentralCrossRef

33.

Nuwayhid N, Johnson G, Feld R. Kinetic measurement of the combined concentrations of acetoacetate and beta-hydroxybutyrate in serum. Clin Chem. 1988;34(9):1790–3.PubMedCrossRef

34.

Nims RW, Darbyshire JF, Saavedra JE, Christodoulou D, Hanbauer I, Cox GW, et al. Colorimetric methods for the determination of nitric oxide concentration in neutral aqueous solutions. Methods. 1995;7(1):48–54.CrossRef

35.

Noeman SA, Hamooda HE, Baalash AA. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol Metab Syndr. 2011;3(1):1–8.CrossRef

36.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clinic J American Soc Nephrology: CJASN. 2009;4(2):337.PubMedCentralCrossRef

37.

Francescato HD, Costa RS, Junior FB, Coimbra TM. Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol Dial Transplant. 2007;22(8):2138–48.PubMedCrossRef

38.

Ortiz A, Navarro-González JF, Núñez J, de la Espriella R, Cobo M, Santamaría R, et al. The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology. Clin Kidney J. 2022;15(5):865–72.PubMedCrossRef

39.

Hutton HL, Ooi JD, Holdsworth SR, Kitching AR. The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology. 2016;21(9):736–44.PubMedCrossRef

40.

Na SW, Jang YJ, Hong MH, Yoon JJ, Lee HS, Kim HY, et al. Protective Effect of Joa-Gui Em through the Improvement of the NLRP3 and TLR4/NF-κb Signaling by Ischemia/Reperfusion-Induced Acute Renal Failure Rats. Evidence-Based Complement Alternat Medic. 2021;2021:1–10.CrossRef

41.

Yu G, Bai Z, Chen Z, Chen H, Wang G, Wang G, et al. The NLRP3 inflammasome is a potential target of ozone therapy aiming to ease chronic renal inflammation in chronic kidney disease. Int Immunopharmacol. 2017;43:203–9.PubMedCrossRef

42.

Qiu Y-y, Tang L-q. Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharmacol Res. 2016;114:251–64.PubMedCrossRef

43.

Mulay SR, Evan A, Anders HJ. Molecular mechanisms of crystal-related kidney inflammation and injury Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrology Dialysis Transplant. 2014;29(3):507–14.CrossRef

44.

Diwan V, Brown L, Gobe GC. Adenine-induced chronic kidney disease in rats. Nephrology. 2018;23(1):5–11.PubMedCrossRef

45.

Eirin A, Textor SC, Lerman LO. Emerging paradigms in chronic kidney ischemia. Hypertension. 2018;72(5):1023–30.PubMedCrossRef

46.

Jia T, Olauson H, Lindberg K, Amin R, Edvardsson K, Lindholm B, et al. A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol. 2013;14(1):116.PubMedPubMedCentralCrossRef

47.

López-Novoa JM, Rodríguez-Peña AB, Ortiz A, Martínez-Salgado C, López Hernández FJ. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Transl Med. 2011;9:1–26.CrossRef

48.

Manivannan J, Shanthakumar J, Silambarasan T, Balamurugan E, Raja B. Diosgenin, a steroidal saponin, prevents hypertension, cardiac remodeling and oxidative stress in adenine induced chronic renal failure rats. RSC Adv. 2015;5(25):19337–44.CrossRef

49.

Sonfack CS, Nguelefack-Mbuyo EP, Kojom JJ, Lappa EL, Peyembouo FP, Fofié CK, et al. The aqueous extract from the stem bark of Garcinia lucida Vesque (Clusiaceae) exhibits cardioprotective and nephroprotective effects in adenine-induced chronic kidney disease in rats. Evidence-Based Complement Alternat Medic. 2021;2021:1–11.CrossRef

50.

Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019;115(4):776–87.PubMedCrossRef

51.

Calado J, Santer R, Rueff J. Effect of kidney disease on glucose handling (including genetic defects). Kidney Int. 2011;79:S7–13.CrossRef

52.

Gorriz JL, Martinez-Castelao A. Proteinuria: detection and role in native renal disease progression. Transplant Rev. 2012;26(1):3–13.CrossRef

53.

Hamdy MM, Abdel-Rahman MS, Badary DM, Sabra MS. Effects of furosemide and tadalafil in both conventional and nanoforms against adenine-induced chronic renal failure in rats. Eur J Med Res. 2022;27(1):1–17.CrossRef

54.

Wei Q, Xiao X, Fogle P, Dong Z. Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. PLoS ONE. 2014;9(9):e106647.PubMedPubMedCentralCrossRef

55.

Sabiullah M. Estimation of serum creatinine, blood urea nitrogen and urine analysis in patients with diabetes to assess the renal impairments. Int J Adv Biochem Res. 2019;3(2):01–4.

56.

Palmer SC, Ruospo M, Teixeira-Pinto A, Craig JC, Macaskill P, Strippoli GF. The validity of drug effects on proteinuria, albuminuria, serum creatinine, and estimated GFR as surrogate end points for ESKD: a systematic review. Am J Kidney Dis. 2018;72(6):779–89.PubMedCrossRef

57.

Weiner ID, Mitch WE, Sands JM. Urea and ammonia metabolism and the control of renal nitrogen excretion. Clinical J American Soc Nephrology: CJASN. 2015;10(8):1444.CrossRef

58.

Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210–5.PubMedCrossRef

59.

Zhao S, Chen F, Yin Q, Wang D, Han W, Zhang Y. Reactive oxygen species interact with NLRP3 inflammasomes and are involved in the inflammation of sepsis: from mechanism to treatment of progression. Front Physiol. 2020;11:571810.PubMedPubMedCentralCrossRef

60.

Sarkar A, Hall MW, Exline M, Hart J, Knatz N, Gatson NT, et al. Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1β and interleukin-18. Am J Respir Crit Care Med. 2006;174(9):1003–10.PubMedPubMedCentralCrossRef

61.

Akhter J, Khan J, Baghel M, Beg MMA, Goswami P, Afjal MA, et al. NLRP3 inflammasome in rosmarinic acid-afforded attenuation of acute kidney injury in mice. Sci Rep. 2022;12(1):1313.PubMedPubMedCentralCrossRef

62.

Li S, Lin Q, Shao X, Mou S, Gu L, Wang L, et al. NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation. Exp Cell Res. 2019;383(1):111488.PubMedCrossRef

63.

Irazabal MV, Torres VE. Reactive oxygen species and redox signaling in chronic kidney disease. Cells. 2020;9(6):1342.PubMedPubMedCentralCrossRef

64.

Descamps‐Latscha B, Drüeke T, Witko‐Sarsat V, editors. Dialysis‐induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 2001;14(3):193–9. https://doi.org/10.1046/j.1525-139x.2001.00052.x.

65.

Modlinger PS, Wilcox CS, Aslam S, editors. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol. 2004;24(4):354–65. https://doi.org/10.1016/j.semnephrol.2004.04.007.

66.

Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochem Biophys Acta. 2012;1826(1):129–69.PubMed

67.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clinical J American Soc Nephrology : CJASN. 2009;4(2):337–44.

68.

Danquah M, Owiredu WKBA, Jnr BAE, Serwaa D, Odame Anto E, Peprah MO, et al. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) as an early biomarker for detection of renal failure in hypertensives: a case–control study in a regional hospital in Ghana. BMC Nephrol. 2023;24(1):114.PubMedPubMedCentralCrossRef

69.

Ali BH, Al Za’abi M, Adham SA, Al Suleimani Y, Karaca T, Manoj P, et al. The effect of sildenafil on rats with adenine—Induced chronic kidney disease. Biomed Pharmacother. 2018;108:391–402.

70.

Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4(2):265–80.PubMedCrossRef

71.

Foresto-Neto O, Ávila VF, Arias SCA, Zambom FFF, Rempel LCT, Faustino VD, et al. NLRP3 inflammasome inhibition ameliorates tubulointerstitial injury in the remnant kidney model. Lab Invest. 2018;98(6):773–82.PubMedCrossRef

72.

Jia T, Olauson H, Lindberg K, Amin R, Edvardsson K, Lindholm B, et al. A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol. 2013;14:1–8.CrossRef

73.

Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A, et al. Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. World journal of nephrology. 2013;2(2):31.PubMedPubMedCentralCrossRef

74.

Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne’s thread. Int J Mol Sci. 2019;20(15):3711.PubMedPubMedCentralCrossRef

75.

Priante G, Gianesello L, Ceol M, Del Prete D, Anglani F. Cell death in the kidney. Int J Mol Sci. 2019;20(14):3598.PubMedPubMedCentralCrossRef

76.

Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18(9):2114–27.PubMedPubMedCentralCrossRef

Title: Adenine model of chronic renal failure in rats to determine whether MCC950, an NLRP3 inflammasome inhibitor, is a renopreventive
Authors: Mahmoud S. Sabra
Fahmy K. Hemida
Essmat A. H. Allam
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-023-03427-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Prevalence of physical frailty and impact on survival in patients with chronic kidney disease: a systematic review and meta-analysis

Impact of a multidisciplinary approach involving clinical pharmacist on resolving drug related problems in chronic kidney patients: a prospective interventional study

Isolated massive histiocytes renal interstitial infiltration: a case report of an unexpected cause of acute kidney injury in a kidney transplant recipient

Hyperkalaemia prevalence and dialysis patterns in Chinese patients on haemodialysis: an interim analysis of a prospective cohort study (PRECEDE-K)

Cystatin C-derived estimated glomerular filtration rate in children with sickle cell anaemia

Risk factors associated with acute kidney injury in a cohort of hospitalized patients with COVID-19

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials